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Abstract
Aims/Hypothesis: Bile acid sequestrants (BAS) reduce plasma glucose levels in type II diabetics and in murine models of
diabetes but the mechanism herein is unknown. We hypothesized that sequestrant-induced changes in hepatic glucose
metabolism would underlie reduced plasma glucose levels. Therefore, in vivo glucose metabolism was assessed in db/db
mice on and off BAS using tracer methodology.
Methods: Lean and diabetic db/db mice were treated with 2% (wt/wt in diet) Colesevelam HCl (BAS) for 2 weeks. Parameters
of in vivo glucose metabolism were assessed by infusing [U-13C]-glucose, [2-13C]-glycerol, [1-2H]-galactose and paracetamol
for 6 hours, followed by mass isotopologue distribution analysis, and related to metabolic parameters as well as gene
expression patterns.
Results: Compared to lean mice, db/db mice displayed an almost 3-fold lower metabolic clearance rate of glucose
(p = 0.0001), a ,300% increased glucokinase flux (p = 0.001) and a ,200% increased total hepatic glucose production rate
(p = 0.0002). BAS treatment increased glucose metabolic clearance rate by ,37% but had no effects on glucokinase flux nor
total hepatic or endogenous glucose production. Strikingly, BAS-treated db/db mice displayed reduced long-chain
acylcarnitine content in skeletal muscle (p = 0.0317) but not in liver (p = 0.189). Unexpectedly, BAS treatment increased
hepatic FGF21 mRNA expression 2-fold in lean mice (p = 0.030) and 3-fold in db/db mice (p = 0.002).
Conclusions/Interpretation: BAS induced plasma glucose lowering in db/db mice by increasing metabolic clearance rate of
glucose in peripheral tissues, which coincided with decreased skeletal muscle long-chain acylcarnitine content.
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Introduction
Type 2 diabetes is a major health problem worldwide [1]. The
predominant features of type 2 diabetes entail increased fasting
blood glucose levels, increased plasma triglycerides and LDL-
cholesterol levels, as well as disturbed peripheral glucose utilization
[2–4]. The use of bile acid sequestrants (BAS) for lowering of LDL-
cholesterol levels is well established [5–7]. More recently,
Colesevelam HCl, a BAS, has been indicated by the FDA to
improve glycemic control in patients with type 2 diabetes [8–10]. So
far, however, the actual changes in hepatic and/or peripheral
glucose metabolism upon BAS supplementation are not understood.
Bile acids are synthesized from cholesterol in the liver. Upon
secretion into bile, bile acids function to emulsify fats in the small
intestine. Most of the secreted biliary bile acids are reabsorbed in
the ileum (enterohepatic circulation). Sequestrants interfere with
the enterohepatic circulation of bile acids by binding them in the
intestine, thereby inhibiting their reabsorption and promoting
their fecal loss. As a consequence, the liver increases bile acid
synthesis and subsequently cholesterol uptake from the circulation
thereby reducing LDL-cholesterol levels [11,12].
To date, there is a lack of understanding how BAS reduce
plasma glucose levels. However, a large body of research suggests
that bile acids modulate hepatic glucose metabolism via signaling
pathways mediated by the nuclear receptor NRH1H4 (Fxr) in
diabetes [13–19]. Fxr is expressed in the liver, intestine, adrenal
gland and kidney [20], and it acts to inhibit de novo bile acid
synthesis when activated by bile acids in the liver [21].
Paradoxically, both agents that inhibit de novo bile acid synthesis,
such as bile acids themselves and synthetic Fxr ligands [14,22], as
well as agents that increase de novo bile acid synthesis such as BAS,
were shown to reduce plasma glucose levels in diabetic mice
[23,24]. Thus, regulation of bile acid-mediated changes in blood
glucose levels remains elusive.
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We therefore questioned whether BAS-induced changes in
hepatic carbohydrate fluxes are responsible for the observed
reduction in plasma glucose levels in db/db mice. To test this, we
treated healthy lean mice and obese, diabetic db/db mice with
Colesevelam HCl. Applying an in vivo infusion protocol of stable
isotopes followed by mass isotopologue distribution analysis
(MIDA), we first characterized specific disruptions of whole body
glucose turnover and hepatic glucose metabolism in db/db mice.
We then tested the hypothesis that BAS restores disrupted hepatic
glucose fluxes thereby mediating the previously observed reduction
in blood glucose levels in diabetic mice. In view of the strong
interaction between glucose and fatty acid metabolism, we
additionally tested the effect of BAS on levels of lipids and
intermediates of fatty acid metabolism in liver and muscle.
Materials and Methods
Animals and diets
Ten week old male lean C57BL/6J and obese, diabetic db/db
mice on a C57BL6/J background (B6.Cg-m +/+ Leprdb/J) were
purchased from Charles River Laboratories (L’Arbresle, France
and Brussels, Belgium, respectively). Mice were housed in a
temperature controlled (21uC) room with a dark-light cycle of 12 h
each. For all animal experiments the principles of laboratory
animal care (NIH publication no. 85–23, revised 1985) were
followed. The Ethics Committee for Animal Experiments of the
University Groningen, the Netherlands, approved experimental
procedures (Experiment ID: DEC5030 University of Groningen).
One week after arrival at the animal facility, 8 db/db (db) and 6
lean (L) mice were put on a diet containing standard laboratory
chow (RMH-B; Arie Blok, Woerden, The Netherlands) supple-
mented with 2% (wt/wt) Colesevelam HCl (Daiichi Sankyo, Inc.,
Parsippany, NJ, USA) for 2 weeks. Another 8 db/db and 6 lean
mice remained on standard laboratory chow. Body weights and
food intake were recorded every other day. Mice were fitted with a
permanent catheter in the right atrium via the jugular vein, as
described previously [25]. Mice were allowed to recover from
surgery for 6 days.
Materials The following isotopes were used: 2-13-C glycerol (99%
13C atom percent excess), [1-2H]-galactose (98% 2H atom percent
excess) (Isotec, Miamisburg, Ohio, USA), [U-13C]-glucose (99%
13C atom percent) (Cambridge Isotope Laboratories, Andover,
Mass., USA). All reagents and chemicals used were reagent pro
analysis grade. Blood spots and urine were collected on Schleicher
and Schuell No. 2992 filter paper (Schleicher and Schuells, ‘s
Hertogenbosch, The Netherlands). Infusates were freshly prepared
and sterilized at the day before the experiment.
Animal Experiments
The infusion experiment was performed in conscious mice, as
described previously [25]. Mice were fasted for 4 hours (03:00–
07:00 am) and then housed in metabolic cages to allow frequent
collection of urine and blood spots on filter paper. Mice were
infused with a sterile solution containing [U-13 C]-glucose
(13.9 mmol/ml), [2-13C]-glycerol (160 mmol/ml), [1-2H]-galactose
(33 mmol/ml) and paracetamol (1.0 mg/ml) at a rate of 0.6 ml/h.
Before and during the experiment, small blood samples were
obtained via tail bleeding to allow for the determination of plasma
glucose. Blood was immediately centrifuged and stored at 220uC
until analysis. Blood spots were collected on filter paper before the
start of the infusion and hourly afterwards until 6 h after the start
of the infusion. Blood spots were air dried and stored at room
temperature until analysis. Hourly urine samples were collected on
filter paper, air dried and stored at room temperature until
analysis. At the end of the experiment, animals were anesthetized
with isoflurane and a small blood sample was collected via orbital
puncture for the determination of insulin.
Mice were allowed to recover and five days after the infusion
experiment. Mice were then fasted for 7 hours (03:00–10:00 h)
and terminated by heart puncture under isoflurane anesthesia. A
large blood sample was collected in heparin-containing tubes,
immediately centrifuged and stored at 220uC until analysis. Liver
was excised, weighed, snap frozen and stored at 280uC until
further analysis. Gastrocnemius and plantaris muscle as well as
epididymal white adipose tissue were collected, frozen in liquid N2
and stored at 280uC until further analysis.
Measurement and Analysis of Mass Isotopologue Distribution
Analysis by GC-MS Analytical procedures for extraction of glucose
in bloodspots and paracetamol-glucuronide from urine filter paper
strips and derivatization of the extracted compounds and GC-MS
measurements of derivatives were all performed according to Van
Dijk et al [26,27]. The measured fractional distribution was
corrected for natural abundance of 13C by multiple linear
regression as described by Lee et al. [28]to obtain the excess mole
fraction of mass isotopologues due to incorporation and dilution of
infused labeled compounds, i.e., [2-13C]-glycerol, [U-13C]-glucose
and [1-2H]-galactose. This distribution was used in mass
isotopologues distribution analysis (MIDA) algorithms of isotope
incorporation and dilution according to Hellerstein et al. [29] as
described by Van Dijk et al [26,27]. Rate of glucose disposal,
metabolic clearance rate, hepatic glucose production rates as well
as the hepatic glucose fluxes are part of MIDA.
Determination of metabolite concentrations
Commercially available kits were used to determine plasma
levels of insulin (Mercodia, Uppsala, Sweden), triglycerides, total
cholesterol, free cholesterol and NEFA (Wako Chemicals, Neuss,
Germany).
Plasma HOMA-index was calculated multiplying the blood
glucose levels by the plasma insulin levels at 6 h of MIDA infusion
and dividing the product by 22.5 [30]. Hepatic glycogen and
glucose-6-phosphate content were determined as previously
described [25]. Hepatic lipids were determined in liver homog-
enates by commercially available kits for triglycerides and total
cholesterol (Wako Chemicals, Neuss, Germany) after lipid
extraction as described by Bligh and Dyer [31]. Plasma
acylcarnitines were determined according to the method of Chase
et al [32] as described by Derks et al. [33]. Profiles of long-chain
acylcarnitines (C16:0, C16:1, C18:0, C18:1 and C18:2) in muscle
and liver homogenates (15% (w/v) in PBS) were determined
according to the method of Gates [33].
mRNA levels
Total RNA was isolated from liver using TRI-reagent (Sigma,
St. Louis, MO) according to the manufacturers’ protocol. cDNA
was produced as described by Plo¨sch and coworkers [34]. Real-
time PCR was performed on a 7900HT FAST real-time PCR
system using FAST PCR master mix and MicroAmp FAST
optical 96 well reaction plates (Applied Biosystems Europe,
Nieuwerkerk ad IJssel, The Netherlands). Primer and probe
sequences have been published before (www.labpediatrics.nl) and
deposited in the RTprimerDB. PCR results were normalized to
18S-rRNA abundance.
Statistics
All values are represented as mean 6 standard deviation.
Statistical significance was assessed using the Mann-Whitney-U-
test (SPSS 12.0.1 for Windows). P-values were corrected for
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multiple comparison errors. Statistical significance was accepted
for a p,0.05.
Results
Bile acid sequestration reduced plasma glucose values in
db/db mice
Previously, it has been observed that Colesevelam HCl
treatment lowers plasma glucose concentrations in db/db mice
compared to untreated counterparts [24]. To confirm and
elaborate these findings, basal parameters related to glucose
metabolism were determined in lean and db/db mice treated with
the bile acid sequestrant (BAS) for two weeks. As expected, BAS-
treatment significantly lowered blood glucose levels of diabetic
mice (Table 1). No effects of BAS on body weight, liver weight or
liver weight/body weight ratio were observed (Table 1). BAS
treatment had no effect on 4 h fasted plasma insulin levels in db/db
mice, while a 30% (non-significant) reduction of plasma insulin
levels occurred at the end of the MIDA infusion experiment
(Table 1). The HOMA-index was significantly improved in
sequestrant-treated diabetic mice compared to untreated counter-
parts. Moreover, we observed a non-significant decrease in plasma
NEFA levels, a more than 50%, however non-significant,
reduction, in plasma 3-hydroxybutyrate levels with no apparent
effect on plasma lactate concentrations (Table 1). Untreated lean
and db/db mice displayed similar plasma triglyceride levels, which
decreased in both models upon BAS-treatment. Plasma cholesterol
levels were slightly, but significantly, elevated in untreated db/db
mice compared to untreated lean mice: we hypothesize this to be
due to decreased activity of FXR which leads to an increase in
hepatic ApoA1 expression as shown in a previous study [35].
Apparently, this effect was stronger in db/db mice than in lean
mice because no significant effect was observed in the latter. We
hypothesize this to be due to decreased activity of FXR which
leads to an increase in ApoA1 confirming data in a previous study.
Apparently, this effect was stronger in db/db mice than WT
because no significant effect was observed in WT mice. Consistent
with our previous observations [24], liver triglyceride contents
were significantly increased in sequestrant-treated lean and db/db
mice compared to controls, (Table 1). Diabetic mice had
significantly higher hepatic glycogen contents compared to lean
mice while, surprisingly, hepatic glucose-6-phosphate contents was
decreased in the db/db genotype, BAS treatment had no effect
herein (Table 1). Additionally, hepatic levels of free fatty acids
were increased ,10-fold in db/db mice with no effect of BAS
(Table 1).
Bile acid sequestration increased metabolic clearance of
glucose without affecting hepatic glucose production
BAS promotes specific changes in hepatic cholesterol and bile
acid synthesis [24]. To gain insight in hepatic glucose metabolism
upon BAS-treatment, in vivo glucose metabolism was studied in
lean and db/db mice after 2 weeks of BAS treatment. First, whole
body and hepatic glucose metabolism in db/db mice was
characterized.
The peripheral tissue disposal of plasma glucose (also regarded
as the amount of glucose taken up by tissues) was significantly
higher in db/db mice compared to lean mice (93.1.613.1 vs.
117.0614.6 mmol.kg21.min21, lean vs. db/db, Table 2), but the
metabolic clearance rate (volume of blood cleared from glucose)
was significantly lower in db/db mice (9.961.3 vs.
Table 1. The effects of bile acid sequestration (BAS) on morphological, plasma and hepatic parameters in lean and diabetic mice.
L L BAS db db BAS
Body weight (g) 23.961.1 24.960.9 37.963.2{ 39.763.5{
Liver weight (g) 1.1460.08 1.1960.09 1.7460.24{ 1.9360.27{
Liver Weight/Body weight (%) 4.760.2 4.760.2 4.660.6 4.960.7
Plasma Parameters 21.360.9 20.960.8 21.963.1 20.963.1
4 hour fasted blood glucose (mmol/L) 8.360.6 8.860.9 27.764.4{ 19.364.8*{
Blood glucose at 6 hour of MIDA infusion (mmol/L) 9.260.5 9.761.0 32.763.9 # 23.163.9*{
4 hour fasted plasma insulin (mU/L) 5.761.5 7.261.4 44.1626.3{ 49.8619.3{
Plasma insulin at 6 hour of MIDA infusion (mUl/L) 6.761.8 7.561.6 66.6623.3{ 48.0618.4{
HOMA Index 1.060.3 1.260.3 34.8610.1{ 16.966.7*{
NEFA 3006109 393692 6976149{ 5556149
Lacate (mmol/L) 8.461.1 8.361.3 6.861.5 8.661.8
3-Hydroxybutyrate (mM) 0.2860.16 0.2860.16 1.560.95* 0.7060.27
Triglycerides (mmol/L) 0.7460.16 0.5260.11* 0.9960.14 0.6760.14{
Total cholesterol (mmol/L) 2.360.3 2.360.2 2.860.1{ 3.260.4*{
Liver Parameters
Triglycerides (mmol/L) 1666 31614* 44611{ 59621*{
Glycogen (mmol/g liver) 62645 47630 175621{ 216637{
Glucose-6-Phosphate (nmol/mg liver) 0.6960.18 0.7460.18 0.4060.16{ 0.4260.10{
Free fatty acids (nmol/g liver) 3666225 5976315 307961503{ 440662013{
7 h fasted parameters (unless otherwise stated) in lean mice (L), lean mice supplemented with BAS (L BAS), db/db (db) and db/db mice supplemented with BAS (db BAS).
Data are shown as means 6 SD;
*p,0.05 vs. same genotype,
{p,0.05 vs. lean same condition.
doi:10.1371/journal.pone.0024564.t001
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3.660.7 ml.kg21.min21, lean vs. db/db, Table 2), because the
plasma glucose concentrations (amount of glucose per volume)
were almost 3 times higher in db/db compared to lean mice
(9.260.5, 32.763.9 mmol/l, lean vs. db/db, Table 1).
A strongly increased hepatic glucose cycling brought about by a
massively increased glucokinase flux was observed in db/db
compared to lean mice (46.764.5 vs. 150.2658.3 mmol.kg21.-
min21, lean vs. db/db, Table 2). In db/db mice de novo synthesis of
glucose-6-phosphate was significantly decreased when com-
pared to lean mice (86.066.0 mmol.kg21.min21 vs. 73.76
10.9 mmol.kg21.min21, lean vs. db/db, p,0.05, Table 2). Endog-
enous glucose production (excluding glucose cycling) was slightly,
but significantly, higher (87.3613.0 vs. 115.0614.0 mmol.kg21.
min21, lean vs. db/db, p,0.05, Table 2) whereas total hepatic
glucose output (including glucose cycling) was massively higher in
db/db compared to lean mice (118.0616.6 mmol/kg21.min21 vs.
243.5654. mmol/kg21.min21 lean and db/db mice, respectively
(Table 2).
BAS treatment had differential effects on whole body glucose
metabolism in lean and db/db mice. Irrespective of the decreased
plasma glucose concentration, BAS treatment had no effect on the
flux through glucokinase in livers of db/db mice. Since the
glucokinase flux remained significantly high, glucose cycling
remained significantly higher in treated db/db mice when
compared to treated lean mice. In treated db/db mice the rate of
endogenous glucose production did not change and the rate of
total hepatic glucose output tended to increase, albeit non-
significantly (Table 2). Although BAS was not effective to reduce
rates of hepatic glucose consumption or production, we did
observe a significant decrease of de novo glucose-6-phosphate
synthesis in treated db/db mice (87.469.4 mmol/kg21.min21 vs.
61.267.4 mmol/kg21.min21, lean vs. db/db mice, p,0.05,
Table 2). This accounted for the significantly decreased contribu-
tion of newly synthesized glucose-6-phosphate towards plasma
glucose (Table 2). Since the flux through glucokinase and glucose
cycling remained significantly high, these decreases of de novo
glucose-6-phosphate synthesis and newly synthesized glucose-6-
phosphate partitioning towards glucose did not translate into a
decreased total glucose output in db/db mice.
Importantly, while the peripheral glucose disposal (amount of
glucose taken up by tissues) was not different in BAS-treated db/db
mice compared to untreated db/db mice, significantly more blood
was cleared of glucose (metabolic clearance rate) in BAS-treated
db/db mice (,37%, Table 2) as blood glucose concentrations were
significantly reduced in -treated db/db mice compared to untreated
db/db mice (,30%, Table 1) indicating a higher affinity of
peripheral tissues to glucose in BAS treated db/db mice. Increased
glucose uptake of glucose will decrease the glucose concentration
until a new steady state is reached at lower glucose concentrations
when there is again a balance between plasma glucose appearance
and disappearance.
To assess whether changes in hepatic glucose metabolism were
in parallel with changes in gene expression patterns, expression
levels of genes involved in hepatic glucose metabolism in untreated
lean and db/db mice were compared. Compared to lean mice, in
db/db mice expression levels of glucose transporter 2, glucokinase,
glucose-6-phosphate hydrolase as well as glucose-6-phosphatase
were increased, while expression levels of genes of b-oxidation like
Table 2. Effects of BAS on in vivo hepatic glucose metabolism.
L LBAS db db BAS
Rate of plasma glucose:
Peripheral tissue disposal (mmol/kg/min) 93613 10769.2 117613{ 11968{
Metabolic clearance rate (ml/kg/min) 9.961.3 10.760.6 3.660.7{ 5.360.3{*
Contributions to endogenous glucose production rate (mmol/kg/min)
De novo glucose-6-phosphate synthesis to
glucose
6067 6468 6666 5668*
Glycogen to glucose 2766 3765* 4968{ 6166{*
Endogenous glucose production rate 87613 10169 115614{ 11766{
Contributions to hepatic glucose production rate (mmol/kg/min)
Endogenous glucose production rate 87613 10169 115614{ 11766{
Glucose cycling rate 3164 3863 129653{ 156653{
Total hepatic glucose production rate 118617 139617 244654{ 273658{
Flux rates (mmol/kg/min)
Glucokinase 4765 5667 150658{ 184654{
Glucose-6-Phosphate de novo synthesis 8666 8769 74611{ 6167{*
In vivo parameters of hepatic glucose metabolism during the last 3 hours of the infusion experiment in lean mice (L), lean mice supplemented with BAS (L BAS), db/db
mice (db) and db/db mice supplemented with BAS (db BAS) are depicted in the table, the graphic Graphic S1 illustrates the individual glucose fluxes for a better
understanding of the table in a schematic manner. The second panel of the table entitled ‘‘Contributions to endogenous glucose production rate’’ shows the
contribution of de novo glucose-6-phosphate synthesis to glucose (displayed as fluxes e+b in Graphic S1) and of glycogen to glucose (displayed as fluxes c+b Graphic
S1) which altogether make up the endogenous glucose production rate. The third panel entitled ‘‘Contributions to hepatic glucose production rate’’ takes into account
the glucose cycling rate and thus shows the contributions of the endogenous glucose production rate and the glucose cycling rate (which consists of the cycling of
glucose: 1. from glucose to glucose-6-phosphate (depicted as a in the graphic, the glucokinase flux) and back (depicted as b in Graphic S1, the glucose-6-phosphatase
flux); 2. Glucose-6-phosphate to glycogen and back, fluxes c+d in Graphic S1; and 3. Gluconeogenesis, flux e in the graphic (glycolysis is also a part of this but cannot be
measured in the present set up) to the total hepatic glucose production rate which equals the flux rate through glucose-6-phosphatase. The lower panel shows the flux
rates through glucokinase (a in the graphic) and the rate of glucose-6-phosphate de novo synthesis (c+e in Graphic S1). Each value represents the mean 6 SD;
*p,0.05 vs. same genotype untreated;
{p,0.05 vs. L same condition.
doi:10.1371/journal.pone.0024564.t002
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acetyl CoA-carboxylase 2 and pyruvate dehydrogenase, were
decreased and no difference was observed in the expression of the
gene encoding phospho-enol-pyruvate carboxykinase nor in
glycogen phopshorylase, glycogen synthase, pyruvate kinase and
carnitine palmitoyltransferase 1. (Table 3). Additionally, expres-
sion levels of these genes were measured in both models following
BAS-treatment. BAS treatment had differential effects on
expression of genes involved in hepatic glucose metabolism. In
lean mice, expression of glucokinase was increased upon BAS
treatment whereas expression levels remained high in db/db mice.
Quite surprisingly, expression of the glycolytic enzyme pyruvate
kinase was strongly increased and phospoenolpyruvate carboxylase
was decreased upon treatment in db/db mice whereas expression
levels remained unaffected in lean mice upon treatment. (Table 3).
Acetyl CoA-carboxylase 2 expression levels of treated db/db mice
increased to that observed in lean control mice. In addition,
hepatic gene expression levels of fibroblast growth factor 21
(FGF21), which has lately gained attention for its remarkable in vivo
actions on glucose metabolism, were measured [36]. Surprisingly,
expression levels of FGF21 were 2-fold increased in treated lean
and 3-fold increased in treated db/db mice compared to untreated
counterparts (Table 3).
Bile acid sequestration reduced long-chain acylcarnitine
content in muscle and plasma in db/db mice
Skeletal muscle is the major site of both glucose and fatty acid
uptake and oxidation [4]. It is known that under circumstances of
high glucose concentrations muscle favors glucose uptake and
oxidation over fatty acid uptake and oxidation [4], while
accumulating excess fatty acids, in particular saturated free fatty
acid species like stearate and palmitate [37,38]. Recently, it has
been shown that excessive fatty acid oxidation in diabetic mice,
results in inefficient oxidation [39]. Concomitantly, high intracel-
lular concentrations of long-chain acylcarnitines, markers of
inefficient mitochondrial fatty acid oxidation, were measured.
High concentrations of these intermediates can impair the switch
to carbohydrate oxidation, a marker of ‘‘metabolic flexibility’’. To
study whether BAS affected fatty acid metabolism, long-chain
acylcarnitine contents in liver and skeletal muscle were measured.
In db/db mice, both skeletal and liver long-chain acylcarnitines
were strongly increased compared to lean mice (Figure 1). BAS
treatment had no effect on hepatic long-chain acylcarnitine
content in db/db mice (Figure 1A). In contrast, in skeletal muscle
of db/db mice a strong reduction of long-chain acylcarnitine
content was observed which almost reached the level of untreated
lean mice (Figure 1B). Specifically saturated long-chain acylcarni-
tine species of palmitic (C16:0) and stearic acid (C18:0) were
affected (Figure 1C). Paralelling the BAS effect on skeletal muscle,
BAS treatment reduced the high levels of plasma acylcarnitines
(Figure 1D) by reducing both short chain and long-chain
acylcarntitines (data not shown). Apparently, increased metabolic
clearance of glucose by peripheral tissue is paralleled by changes in
long-chain acylcarnitine content of muscle indicative of increased
efficiency of mitochondrial fatty acid oxidation.
Discussion
The leptin receptor deficient db/db mouse is a widely utilized
mouse model of type 2 diabetes as it displays several of the features
of human type 2 diabetes at 12 weeks of age [40]. However, no
characterization describing disturbances of in vivo hepatic glucose
metabolism in this mouse model is available. Here, we first show
that leptin receptor deficiency results in a variety of alterations of in
vivo hepatic glucose metabolism, the most prominent perturbations
being the massively increased glucokinase flux and glucose cycling
in db/db mice. Secondly, we tested whether the bile acid se-
questrant Colesevelam (BAS) induces its reported blood glucose-
lowering actions [23,24] by specific alterations of in vivo hepatic
glucose metabolism. Our results, however, demonstrate that BAS
treatment increased metabolic clearance of glucose by peripheral
tissue without affecting hepatic glucose production. Intrigiungly,
we observed a decrease in skeletal muscle long-chain acylcarnitine
content in treated db/db mice. We speculate this lowering in
skeletal muscle long-chain acylcarnitines to be indicative of an
improved skeletal muscle insulin sensitivity and glucose uptake.
A major and novel observation of this study concerns the
disturbances in in vivo hepatic glucose metabolism in db/db mice.
Most strikingly, glucokinase flux was drastically increased in db/db
mice compared to lean mice. Irrespective the dramatic increase of
the HOMA index in db/db compared to lean mice, the metabolic
clearance of glucose by the liver was essentially not affected.
Moreover, a similar ineffectiveness of insulin to modulate hepatic
glucose metabolism was apparent from the data on de novo
synthesis of glucose-6-phosphate: biosynthesis of glucose-6-phos-
phate was only slightly decreased (,20%) in db/db compared to
lean mice. Moreover, fluxes through glucokinase and de novo
glucose-6-phosphate synthesis were insensitive towards changes in
insulin concentration.
Secondly, we studied whole body glucose metabolism. We
found the metabolic clearance rate of glucose by peripheral organs
was ,3-fold lower in db/db mice at blood glucose concentrations
more than 3 times higher and plasma insulin concentrations ,7.5
times higher than those of lean mice. It is of interest to compare
the hepatic clearance of glucose by glucokinase (as derived by
Table 3. mRNA expression levels.
L LBAS db db BAS
Gluconeogenesis
Phosphoenolpyruvate
carboxylase
1.060.3 0.860.2 1.060.2 0.760.2*
Glyogen phosphorylase 1.060.2 0.960.2 1.060.1 1.060.1
Glucose-6-phosphate
hydrolase
1.060.2 1.260.4 2.961.5{ 3.761.1{
Glucose-6-phosphatase 1.060.2 1.260.4 1.760.3{ 1.860.3{
Glycogen synthase 1.060.3 0.860.2 0.960.1 1.060.1
Glycolysis
Glucose transporter 2 1.060.3 1.260.2 1.460.3{ 1.660.2{
Glucokinase 1.060.3 1.760.5* 1.860.6{ 2.360.3{
Pyruvate kinase 1.060.3 0.960.3 1.160.2 2.160.4{*
b-oxidation
Acetyl CoA-carboxylase 2 1.060.2 1.160.4 0.560.1{ 1.060.2*
Carnitine
palmitoyltransferase 1
1.060.6 1.260.3 0.960.2 0.860.1{
Pyruvate dehydrogenase 1.060.5 0.860.5 0.560.2{ 0.860.2{
Fibroblast growth factor 21 1.060.3 2.161.0* 0.660.2 2.660.8*
Hepatic mRNA expression levels of genes involved in hepatic glucose
metabolism in lean (L, n = 5), lean mice supplemented with BAS (LBAS, n = 6),
db/db mice (db, n = 8) and db/db mice supplemented with BAS (db BAS, n = 8).
Expression of genes was normalized to 18S-rRNA levels. 18S-rRNA levels were
similar in livers of all animals. Each value represents the mean 6 SD;
*p,0.05 vs. same genotype untreated;
{p,0.05 vs. L same condition.
doi:10.1371/journal.pone.0024564.t003
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dividing blood glucose by the glucokinase flux) with values
obtained for peripheral glucose clearance in db/db mice. In db/
db mice, peripheral clearance of glucose was strongly reduced,
whereas hepatic clearance of glucose by glucokinase was hardly
affected compared to lean mice (5.160.7 ml.kg21.min21 vs.
4.660.7 ml.kg21.min21, lean vs. db/db mice, data not shown in
the results section), the observed increase in glucose cycling is most
likely driven by the extreme hyperglycemia in db/db mice.
Furthermore, the rate of gluconeogenesis was hardly affected by
the prevailing high glucose and insulin concentrations in db/db
mice. Similar observations were made previously by us in ob/ob
mice [25]. It clearly indicates that the increase in blood glucose
concentration in both db/db and ob/ob mice is driven by an
impaired uptake and metabolism of glucose in peripheral organs
rather than by increased hepatic glucose production.
Treatment with BAS has been shown to reduce plasma glucose
levels in Type 2 diabetic humans [41,42] and rodents [23,24]. We
tested whether the glucose-lowering actions of BAS in db/db mice
were due to improvement of disturbed hepatic glucose metabo-
lism. Plasma glucose concentration and de novo glucose-6-
phosphate synthesis decreased upon BAS treatment in db/db
mice. Furthermore, insulin concentration tended to decrease,
albeit not significantly, when compared to untreated db/db mice.
The glucokinase flux as well as the glucose cycling rate, however,
remained invariantly high. Thus, changes in liver glucose
metabolism do not mediate the glucose-lowering effect of BAS.
Intriguingly, we also observed an increase in hepatic triglyceride
content in BAS treated db/db mice concomitant with an increased
hepatic pyruvate kinase expression, likely due to induction of
lipogenesis, which we previously described for this model upon
BAS treatment [24]. High demand on precursors of cholesterol to
bile acids and lipogenesis impairs the TCA cycle. Additionally,
phosphoenolpyruvate carboxylase expression was decreased in db/
db mice upon BAS. Apparently, the flux of carbons and of the
TCA cycle needs to be diminished to deliver enough precursors to
these biosynthetic processes.
Lipogenesis is often associated with impaired insulin sensitivity.
However, to date the relationship between insulin sensitivity and
hepatic triglyceride levels is not straight forward and fatty liver
does not necessarily result in insulin resistance. For example, fatty
liver induced by an Lxr-agonist resulted in improved whole body
insulin sensitivity, lowered blood glucose levels and increased
metabolic glucose clearance in ob/ob mice while increasing hepatic
triglyceride levels [43]. Moreover, adding an Lxr-agonist to
healthy mice induced hepatic steatosis while not affecting blood
glucose levels, whole-body insulin sensitivity nor metabolic
clearance rate [43]]. Yet, we found that BAS improved peripheral
glucose clearance in db/db mice. Interestingly, long-chain
acylcarnitine content in db/db skeletal muscle, specifically long-
chain acylcarnitines of palmitic and stearic acid, decreased upon
BAS treatment. Acylcarnitines are by-products of mitochondrial
fatty acid oxidation and are formed upon acyl transfer from acyl-
CoA to carnitine. Composition and content of acylcarnitines can
reflect both high and low rates of mitochondrial fatty acid
oxidation. In inborn errors of mitochondrial fatty acid oxidation,
in which fatty acid oxidation is impaired, acylcarnitines typically
accumulate in tissues and plasma. Additionally, it has been shown
that excessive fatty acid oxidation in diabetic mice results in
inefficient oxidation. Increased content of long-chain acylcarni-
tines in skeletal muscle of db/db mice compared to lean mice could
therefore be indicative of impaired oxidation of long-chain fatty
acids in skeletal muscle mitochondria [39]. This results in
metabolic inflexibility, i.e., the switch to glucose oxidation cannot
be made and insulin is unable to stimulate glucose oxidation [44].
BAS treatment resulted in a clear-cut decrease of long-chain
acylcarnitine content of skeletal muscle in db/db mice only, nearly
to the level that was observed in lean mice. This is suggestive of a
more efficient mitochondrial fatty acid oxidation. Concomitantly,
a higher metabolic clearance rate of glucose was observed,
indicative of an increased ability of the mitochondria to switch to
carbohydrate oxidation and indicative of an improved insulin
sensitivity. While we report an increased glucose metabolic
Figure 1. Effect of BAS on liver, skeletal muscle and plasma acylcarnitines. Effect of BAS on hepatic long-chain acylcarnitines content (Sum
of C16:0, C16:1, C18:0, C18:1 and C18:2) (A), skeletal muscle long-chain acylcarnitines content (B), skeletal muscle saturated long-chain acylcarnitines
content (C) and plasma acylcarnitine concentration (D) in lean mice (L, (n = 5), lean mice supplemented with BAS (L BAS, n = 4), db/db mice (db, n = 5)
and db/db mice supplemented with BAS (db BAS, n = 5). Data are mean6 SD; { p,0.05 vs. L same condition; * p,0.05 vs. same genotype untreated.
doi:10.1371/journal.pone.0024564.g001
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clearance rate and decreased skeletal muscle content of long-chain
acylcarnitines upon BAS treatment in db/db mice, we did not
observe an effects of BAS treatment on mRNA expression levels of
glucose metabolism related genes in peripheral tissues, such as
skeletal muscle and white adipose tissue (Table S1).
We also observed an increased ileal expression of glucagon-like-
peptide-1 (data not shown), which has been associated with an
improved insulin sensitivity [45]. Concomitantly, we also found a
BAS-induced massive malabsorption of dietary fatty acids in lean
and db/db mice (data not shown), indicative of an impaired micelle
formation and thus an increased amount o fatty acids passing
through the distal parts of the intestine upon BAS treatment. It
previously has been described that that fatty acids can induce
GLP-1 by stimulation of L-cells in the ileum [46,47]. Indeed, very
recent work by Shang et al showed that 8 week dietary addition of
BAS in insulin-resistant, diet-induced obese rats led to an
increased Glp-1 release during an oral glucose tolerance test while
plasma glucose and insulin concentrations decreased compared to
untreated insulin-resistant diet-induced obese rats [48]. The
question arises how BAS treatment, which interrupts the
enterohepatic circulation of bile acids, can exerts its beneficial
effects in peripheral tissues. Bile acids have been shown to increase
peripheral energy utilization via activation of the bile acid receptor
TGR5 [49]. However, in our previous study we showed that BAS
treatment does lower the bile acid concentration in plasma by 30%
which should lower rather than increase TGR5 signalling.
Intriguingly. We observed that BAS induced a 2-fold increase in
hepatic FGF21 gene expression in lean and 3-fold increase in db/
db mice. Overexpression of FGF21 in livers of db/db or ob/ob mice
or administration of recombinant FGF21 to db/db or ob/ob mice or
to diabetic Zucker rats have been shown to have beneficial effects
on insulin sensitivity and glucose clearance due to FGF21 actions
on adipose tissue [36,50,51]. In addition to FGF21’s action on
adipose tissue it has recently also been shown to affect muscle
tissue [52]. In this respect, FGF21 might provide a link to
communicate changes in liver metabolism to peripheral tissues to
allow for metabolic adaptation. However, analysis of mRNA
expression levels of genes associated with FGF21 in skeletal muscle
and white adipose tissue of lean and db/db mice treated and not
treated with BAS did not provide any further clues herein (Table
S2). Thus the role of FGF21 as a link to communicate modulations
in liver metabolism and peripheral tissues remains largely elusive
at the moment.
In conclusion, this study is the first to characterize hepatic
glucose fluxes in db/db mice. Glucokinase flux and rates of hepatic
glucose output were massively increased in these mice compared
to lean mice. Additionally, db/db mice had lower metabolic
clearance rates of glucose by peripheral tissues compared to lean
mice. Decreased plasma glucose levels upon BAS treatment were
mainly attributable to increased metabolic clearance of glucose by
peripheral tissues: hepatic glucose output remained unaffected.
Interestingly, skeletal muscle long-chain acylcarnitine content was
decreased in BAS-treated db/db mice. Increased hepatic FGF21
gene expression levels might play a role in modulating peripheral
glucose handling upon BAS-treatment. This hypothesis, however,
requires further investigation.
Supporting Information
Table S1 Skeletal muscle and white adipose tissue
mRNA expression levels of genes implicated in glucose
metabolism. Skeletal muscle and white adipose mRNA
expression levels of genes implicated in glucose metabolism in
7h-fasted lean (L, n = 5), lean mice supplemented with BAS
(LBAS, n= 6), db/db mice (db, n= 8) and db/db mice supplement-
ed with BAS (db BAS, n = 8). Expression of genes was normalized
to 18S-mRNA levels. 18S-mRNA levels were similar in tissues.
(DOC)
Table S2 White adipose and skeletal muscle mRNA
expression levels of genes associated with FGF21. White
adipose and skeletal muscle mRNA expression levels of genes
associated with FGF21 in 7h-fasted lean (L, n = 5), lean mice
supplemented with BAS (LBAS, n= 6), db/db mice (db, n= 8) and
db/db mice supplemented with BAS (db BAS, n = 8). Expression of
genes was normalized to 18S-mRNA levels. 18S-mRNA levels
were similar in tissues of all animals. Each value represents the
mean 6 SD; *p,0.05 vs. same genotype untreated; {p,0.05 vs. L
same condition.
(DOC)
Graphic S1 The graphic illustrates the individual
glucose fluxes for a better understanding of Table 2 in
a schematic manner. The second panel of the table entitled
‘‘Contributions to endogenous glucose production rate’’ shows the
contribution of de novo glucose-6-phosphate synthesis to glucose
(displayed as fluxes e+b in the graphic) and of glycogen to glucose
(displayed as fluxes c+b in the graphic) which altogether make up
the endogenous glucose production rate. The third panel entitled
‘‘Contributions to hepatic glucose production rate’’ takes into
account the glucose cycling rate and thus shows the contributions
of the endogenous glucose production rate and the glucose cycling
rate (which consists of the cycling of glucose: 1. from glucose to
glucose-6-phosphate (depicted as a in the graphic, the glucokinase
flux) and back (depicted as b in the graphic, the glucose-6-
phosphatase flux); 2. Glucose-6-phosphate to glycogen and back,
fluxes c+d in the graphic; and 3. Gluconeogenesis, flux e in the
graphic (glycolysis is also a part of this but cannot be measured in
the present set up) to the total hepatic glucose production rate
which equals the flux rate through glucose-6-phosphatase. The
lower panel shows the flux rates through glucokinase (a in the
graphic) and the rate of glucose-6-phosphate de novo synthesis (c+e
in the graphic).
(DOC)
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